Prognostic value of ERCC1, RRM1, and TS proteins in patients with resected non-small cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 75, Issue 4, 2015, Pages 861-867

  He, Yu Wen ^a   Zhao, Mei Ling ^a   Yang, Xin Yun ^a   Zeng, Jun ^a   Deng, Qiu Hua ^a   He, Jian Xing ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; Excision repair cross complementation group 1; Non small cell lung cancer; Ribonucleotide reductase M1; Thymidylate synthase

Indexed keywords

CARBOPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; PEMETREXED; PROTEIN; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M1; TS PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; GLUTAMIC ACID DERIVATIVE; GUANINE; RRM1 PROTEIN, HUMAN; THYMIDYLATE SYNTHASE; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CHINESE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOKING; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; CLINICAL TRIAL; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; LUNG NEOPLASMS; METABOLISM; PREDICTIVE VALUE; PROSPECTIVE STUDY;

AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CHINA; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; DRUG ADMINISTRATION SCHEDULE; ENDONUCLEASES; GLUTAMATES; GUANINE; HUMANS; IMMUNOHISTOCHEMISTRY; INDIVIDUALIZED MEDICINE; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; THYMIDYLATE SYNTHASE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84925500983     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-015-2714-y     Document Type: Article

References (38)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69-90
2. McCloskey P, Balduyck B, Van Schil PE, Faivre-Finn C, O'Brien M (2013) Radical treatment of non-small cell lung cancer during the last 5 years. Eur J Cancer 49(7):1555-1564
3. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J, International Adjuvant Lung Cancer Trial Collaborative G (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350(4):351-360
4. Geiger S, Schlemmer M, Heinemann V, Stemmler HJ (2010) Adjuvant cisplatin-based chemotherapy for resected NSCLC: one size fits all? Anticancer Drugs 21(9):799-804
5. Arriagada R, Dunant A, Pignon JP, Bergman B, Chabowski M, Grunenwald D, Kozlowski M, Le Pechoux C, Pirker R, Pinel MI, Tarayre M, Le Chevalier T (2010) Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol 28(1):35-42
6. Filipits M, Pirker R (2011) Predictive markers in the adjuvant therapy of non-small cell lung cancer. Lung Cancer 74(3):355-363
7. Maus MK, Mack PC, Astrow SH, Stephens CL, Zeger GD, Grimminger PP, Hsiang JH, Huang E, Li T, Lara PN, Danenberg KD, Gandara DR (2013) Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapy. J Thorac Oncol 8(5):582-586
8. Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C, Provencio M, Isla D, Taron M, Diz P, Artal A, Spanish Lung Cancer G (2004) Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10(4):1318-1325
9. Rouquette I, Mazieres J (2011) A brief overview of a lung cancer biomarker: thymidylate synthase. Rev Mal Respir 28(6):773-777
10. Yokomise H, Liu D, Chang S, Go T, Ishikawa S, Misaki N, Nakashima N (2013) Biomarkers as prognostic factors for cN2 or 3 non-small cell lung cancer treated by induction chemoradiotherapy and surgery. Anticancer Res 33(3):1107-1115
11. Bergot E, Levallet G, Campbell K, Dubois F, Lechapt E, Zalcman G (2013) Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy. Eur Respir Rev 22(130):565-576
12. Passaro A, Palazzo A, Trenta P, Mancini ML, Morano F, Cortesi E (2012) Molecular and clinical analysis of predictive biomarkers in non-small-cell lung cancer. Curr Med Chem 19(22):3689-3700
13. Azuma K, Komohara Y, Sasada T, Terazaki Y, Ikeda J, Hoshino T, Itoh K, Yamada A, Aizawa H (2007) Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci 98(9):1336-1343
14. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC, Investigators IB (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355(10):983-991
15. Nicolson MC, Fennell DA, Ferry D, O'Byrne K, Shah R, Potter V, Skailes G, Upadhyay S, Taylor P, Andre V, Nguyen TS, Myrand SP, Visseren-Grul C, Das M, Kerr KM (2013) Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial. J Thorac Oncol 8(7):930-939
16. Shimizu T, Nakanishi Y, Nakagawa Y, Tsujino I, Takahashi N, Nemoto N, Hashimoto S (2012) Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer. Anticancer Res 32(10):4589-4596
17. Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haura E, Antonia S, Fischer JR (2013) Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 31(19):2404-2412
18. Besse B, Olaussen KA, Soria JC (2013) ERCC1 and RRM1: ready for prime time? J Clin Oncol 31(8):1050-1060
19. De Dosso S, Zanellato E, Nucifora M, Boldorini R, Sonzogni A, Biffi R, Fazio N, Bucci E, Beretta O, Crippa S, Saletti P, Frattini M (2013) ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy. Cancer Chemother Pharmacol 72(1):159-165
20. Hubner RA, Riley RD, Billingham LJ, Popat S (2011) Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations. PLoS One 6(10):e25164
21. Friboulet L, Barrios-Gonzales D, Commo F, Olaussen KA, Vagner S, Adam J, Goubar A, Dorvault N, Lazar V, Job B, Besse B, Validire P, Girard P, Lacroix L, Hasmats J, Dufour F, Andre F, Soria JC (2011) Molecular characteristics of ERCC1-negative versus ERCC1-positive tumors in resected NSCLC. Clin Cancer Res 17(17):5562-5572
22. Gyorffy B, Surowiak P, Budczies J, Lanczky A (2013) Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One 8(12):e82241
23. Lee SH, Noh KB, Lee JS, Lee EJ, Min KH, Hur GY, Lee SH, Lee SY, Kim JH, Lee SY, Shin C, Shim JJ, Kim CH, Kang KH, In KH (2013) Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin. Lung Cancer 81(1):102-108
24. Pesta M, Kulda V, Fiala O, Safranek J, Topolcan O, Krakorova G, Cerny R, Pesek M (2012) Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer. Anticancer Res 32(11):5003-5010
25. Olaussen KA, Mountzios G, Soria JC (2007) ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. Curr Opin Pulm Med 13(4):284-289
26. Seyhan EC, Altin S, Cetinkaya E, Sokucu S, Abali H, Buyukpinarbasili N, Fener N (2011) Prognostic significance of ERCC1 expression in resected non small cell lung carcinoma. Ann Thorac Cardiovasc Surg 17(2):110-117
27. Simon GR, Sharma S, Cantor A, Smith P, Bepler G (2005) ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 127(3):978-983
28. Sodja E, Knez L, Kern I, Ovcaricek T, Sadikov A, Cufer T (2012) Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy. Eur J Cancer 48(18):3378-3385
29. Tantraworasin A, Saeteng S, Lertprasertsuke N, Arayawudhikul N, Kasemsarn C, Patumanond J (2013) The prognostic value of ERCC1 and RRM1 gene expression in completely resected non-small cell lung cancer: tumor recurrence and overall survival. Cancer Manag Res 5:327-336
30. Vassalou H, Stathopoulos E, Fiolitaki G, Koutsopoulos A, Voutsina A, Georgoulias V, Mavroudis D (2013) Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy. Lung Cancer 82(2):324-329
31. Yan D, Wei P, An G, Chen W (2013) Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer. J Cardiothorac Surg 8:149
32. Ozdemir O, Ozdemir P, Veral A, Uluer H, Ozhan MH (2013) ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy. Asian Pac J Cancer Prev 14(8):4679-4683
33. Friboulet L, Olaussen KA, Pignon JP, Shepherd FA, Tsao MS, Graziano S, Kratzke R, Douillard JY, Seymour L, Pirker R, Filipits M, Andre F, Solary E, Ponsonnailles F, Robin A, Stoclin A, Dorvault N, Commo F, Adam J, Vanhecke E, Saulnier P, Thomale J, Le Chevalier T, Dunant A, Rousseau V, Le Teuff G, Brambilla E, Soria JC (2013) ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 368(12):1101-1110
34. Friboulet L, Postel-Vinay S, Sourisseau T, Adam J, Stoclin A, Ponsonnailles F, Dorvault N, Commo F, Saulnier P, Salome-Desmoulez S, Pottier G, Andre F, Kroemer G, Soria JC, Olaussen KA (2013) ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform. Cell Cycle 12(20):3298-3306
35. Fukushima M, Fujioka A, Uchida J, Nakagawa F, Takechi T (2001) Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo. Eur J Cancer 37(13):1681-1687
36. Toffart AC, Timsit JF, Couraud S, Merle P, Moro-Sibilot D, Perol M, Mastroianni B, Souquet PJ, Girard N, Jeannin G, Romand P, Chatellain P, Vesin A, Brambilla C, Brambilla E (2014) Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study). Lung Cancer 83(2):182-188
37. Zhang W, Guo N, Yu C, Wang H, Zhang Y, Xia H, Yu J, Lu J (2012) Differential expression of ERCC-1 in the primary tumors and metastatic lymph nodes of patients with non-small cell lung cancer adenocarcinoma. Tumour Biol 33(6):2209-2216
38. Pierceall WE, Olaussen KA, Rousseau V, Brambilla E, Sprott KM, Andre F, Pignon JP, Le Chevalier T, Pirker R, Jiang C, Filipits M, Chen Y, Kutok JL, Weaver DT, Ward BE, Soria JC (2012) Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses. Ann Oncol 23(9):2245-2252